{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:07:08Z","timestamp":1759133228460,"version":"3.44.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.amjms.2020.05.044","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T20:05:30Z","timestamp":1591041930000},"page":"216-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Is Inhaled Furosemide a Potential Therapeutic for COVID-19?"],"prefix":"10.1016","volume":"360","author":[{"given":"Anja","family":"Brennecke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Villar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Autumn","family":"Meek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Barden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2042-6220","authenticated-orcid":false,"given":"Donald F.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.amjms.2020.05.044_bib0001","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.2020.0757","article-title":"Coronavirus infections-more than just the common cold","volume":"323","author":"Paules","year":"2020","journal-title":"JAMA"},{"unstructured":"World Health Organization. Coronavirus Disease 2019: Situation Report \u2013 92. Available at:https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports; 2020. Accessed April 22, 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0002"},{"year":"2020","author":"Cascella","series-title":"Features, Evaluation and Treatment Coronavirus (COVID-19)","key":"10.1016\/j.amjms.2020.05.044_bib0003"},{"key":"10.1016\/j.amjms.2020.05.044_bib0004","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J Crit Care"},{"issue":"5","key":"10.1016\/j.amjms.2020.05.044_bib0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.amjms.2020.05.044_bib0006","doi-asserted-by":"crossref","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"issue":"10223","key":"10.1016\/j.amjms.2020.05.044_bib0007","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2020.05.044_bib0008","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.amjms.2020.05.044_bib0009","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"unstructured":"Peking University First Hospital. Favipiravir Combined with Tocilizumab in the Treatment of Corona Virus Disease 2019. Identifier NCT04310228. Available at: https:\/\/ClinicalTrials.gov; 2020. Accessed May 8. 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0010"},{"issue":"20","key":"10.1016\/j.amjms.2020.05.044_bib0011","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"unstructured":"Regeneron Pharmaceuticals, Sanofi. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. Identifier NCT04315298. Available at: https:\/\/ClinicalTrials.gov; 2020. Accessed May 9, 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0012"},{"unstructured":"Zhou L, Xu H. A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia COVID-19. Identifier ChiCTR2000030089. Chinese Clinical Trial Register, Available at: http:\/\/www.chictr.org.cn; 2020. Accessed May 8, 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0013"},{"issue":"9","key":"10.1016\/j.amjms.2020.05.044_bib0014","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/kex221","article-title":"Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report","volume":"56","author":"Anger","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.amjms.2020.05.044_bib0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1081-1206(10)62870-0","article-title":"Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells","volume":"83","author":"Yuengsrigul","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.amjms.2020.05.044_bib0016","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.intimp.2013.08.018","article-title":"The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation","volume":"17","author":"Lee","year":"2013","journal-title":"Int Immunopharmacol"},{"year":"2001","author":"Hardman","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","key":"10.1016\/j.amjms.2020.05.044_bib0017"},{"issue":"2","key":"10.1016\/j.amjms.2020.05.044_bib0018","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1681\/ASN.V72345","article-title":"Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid","volume":"7","author":"Pichette","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.amjms.2020.05.044_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM199808063390607","article-title":"Diuretic therapy","volume":"339","author":"Brater","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1152\/ajplegacy.1973.225.1.119","article-title":"Furosemide effect on isolated perfused tubules","volume":"225","author":"Burg","year":"1973","journal-title":"Am J Physiol"},{"key":"10.1016\/j.amjms.2020.05.044_bib0021","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3181\/00379727-118-29835","article-title":"Experiences with Furosemide in Renal Disease","volume":"118","author":"Berman","year":"1965","journal-title":"Proc Soc Exp Biol Med"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0022","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3181\/00379727-123-31391","article-title":"Absorption and excretion of furosemide-S35 in human subjects","volume":"123","author":"Calesnick","year":"1966","journal-title":"Proc Soc Exp Biol Med"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01059438","article-title":"Pharmacokinetics\/pharmacodynamics of furosemide in man: a review","volume":"7","author":"Benet","year":"1979","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0024","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1146\/annurev.pa.16.040176.001221","article-title":"Diuretics: sites and mechanisms of action","volume":"16","author":"Jacobson","year":"1976","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.amjms.2020.05.044_bib0025","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/clpt.1980.111","article-title":"Renal tubular secretion and effects of furosemide","volume":"27","author":"Odlind","year":"1980","journal-title":"Clin Pharmacol Ther"},{"issue":"8605","key":"10.1016\/j.amjms.2020.05.044_bib0026","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0140-6736(88)92540-8","article-title":"Prevention of exercise-induced bronchoconstriction by Inhled Frusemide","volume":"332","author":"Bianco","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.amjms.2020.05.044_bib0027","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00045391-200207000-00009","article-title":"Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases","volume":"9","author":"Prandota","year":"2002","journal-title":"Am J Ther"},{"issue":"4","key":"10.1016\/j.amjms.2020.05.044_bib0028","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/NJH.0b013e3181b06227","article-title":"Nebulized furosemide for the treatment of dyspnea","volume":"11","author":"Owens","year":"2009","journal-title":"J Hosp Palliat Nurs"},{"issue":"7","key":"10.1016\/j.amjms.2020.05.044_bib0029","first-page":"900","article-title":"The role of inhaled opioids and furosemide for the treatment of dyspnea","volume":"52","author":"Kallet","year":"2007","journal-title":"Respir Care"},{"key":"10.1016\/j.amjms.2020.05.044_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1203\/00006450-199604001-00096","article-title":"Decrease cytokine production from human peripheral blood mononuclear cells (PBMCs) by Furosemide","volume":"39","author":"Yuengsrigul","year":"1996","journal-title":"Pediatr Res"},{"issue":"5","key":"10.1016\/j.amjms.2020.05.044_bib0031","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/01.hjh.0000222762.84605.03","article-title":"Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy","volume":"24","author":"Xu","year":"2006","journal-title":"J Hypertens"},{"unstructured":"University of North Carolina, Chapel Hill, Duke University, Eunice Kennedy Shriver National Institute of Child Health and Human Development, The Emmes Company LLC. Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD). Identifier NCT02527798. Available at: https:\/\/ClinicalTrials.gov; 2015. Accessed May 8, 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0032"},{"unstructured":"Armed Forces Hospital Pakistan. Role of Salbutamol and Furosemide in TTN. Identifier NCT03208894. Available at: https:\/\/ClinicalTrials.gov; 2016. Accessed May 8, 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0033"},{"unstructured":"University of Cologne. Trial on Treatment with Inhaled Furosemide of Preterm and Term Neonates with Transient Tachypnoea. Identifier NCT01407848. Available at: https:\/\/ClinicalTrials.gov 2012. Accessed May 8, 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0034"},{"unstructured":"McGill University. Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness. Identifier NCT01851980. Available at: https:\/\/ClinicalTrials.gov; 2016. Accessed May 8, 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0035"},{"unstructured":"Oxford Brookes University. Specificity of Dyspnoea Relief with Inhaled Furosemide. Identifier NCT02881866. Available at: https:\/\/ClinicalTrials.gov; 2015. Accessed May 8, 2020.","key":"10.1016\/j.amjms.2020.05.044_bib0036"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0037","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12931-018-0886-9","article-title":"Inhaled furosemide for relief of air hunger versus sense of breathing effort: a randomized controlled trial","volume":"19","author":"Grogono","year":"2018","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.resp.2006.07.004","article-title":"Effect of inhaled furosemide on air hunger induced in healthy humans","volume":"156","author":"Moosavi","year":"2007","journal-title":"Respir Physiol Neurobiol"},{"issue":"6","key":"10.1016\/j.amjms.2020.05.044_bib0039","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1164\/ajrccm.161.6.9910009","article-title":"Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea","volume":"161","author":"Nishino","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.amjms.2020.05.044_bib0040","first-page":"246","article-title":"Efficacy of nebulized furosemide in children with moderate attack of asthma","volume":"24","author":"Alshehri","year":"2005","journal-title":"West Afr J Med"},{"issue":"2","key":"10.1016\/j.amjms.2020.05.044_bib0041","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1157\/13086747","article-title":"Effectiveness of nebulized furosemide added to nebulized salbutamol in children with acute asthma","volume":"34","author":"Nuho\u011flu","year":"2006","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"4","key":"10.1016\/j.amjms.2020.05.044_bib0042","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/02770909709067218","article-title":"Furosemide given by inhalation ameliorates acute exacerbation of asthma","volume":"34","author":"Ono","year":"1997","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0043","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/02770909809055409","article-title":"Effect of inhaled furosemide in acute asthma","volume":"35","author":"Pendino","year":"1998","journal-title":"J Asthma"},{"issue":"2","key":"10.1016\/j.amjms.2020.05.044_bib0044","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ppul.1950180207","article-title":"Reversal of bronchial obstruction in children with mild stable asthma by aerosolized furosemide","volume":"18","author":"Chin","year":"1994","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.amjms.2020.05.044_bib0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.resp.2017.08.010","article-title":"Aerosol furosemide for dyspnea: high-dose controlled delivery does not improve effectiveness","volume":"247","author":"Banzett","year":"2018","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.amjms.2020.05.044_bib0046","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1006\/viro.1996.0249","article-title":"Reduction of human immunodeficiency virus production and cytopathic effects","volume":"219","author":"Voss","year":"1996","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0047","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0042-6822(89)90105-0","article-title":"The role of monovalent cation transport in Sindbis virus maturation and release","volume":"172","author":"Ulug","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.amjms.2020.05.044_bib0048","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1099\/0022-1317-74-8-1519","article-title":"The effects of lithium and potassium on macromolecular synthesis in herpes simplex virus-infected cells","volume":"74","author":"Hartley","year":"1993","journal-title":"J Gen Virol"},{"issue":"12","key":"10.1016\/j.amjms.2020.05.044_bib0049","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00705-006-0824-x","article-title":"Ionic Contra-Viral Therapy (ICVT); a new approach to the treatment of DNA virus infections","volume":"151","author":"Hartley","year":"2006","journal-title":"Arch Virol"},{"issue":"5","key":"10.1016\/j.amjms.2020.05.044_bib0050","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/bjd.17583","article-title":"A randomized controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts","volume":"180","author":"Rijsbergen","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.amjms.2020.05.044_bib0051","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bcp.2018.08.013","article-title":"Bumetanide attenuates acute lung injury by suppressing macrophage activation","volume":"156","author":"Hung","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0052","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jtcvs.2016.09.068","article-title":"Inhibition of Na-K-Cl cotransporter isoform 1 reduces lung injury induced by ischemia-reperfusion","volume":"153","author":"Lan","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"10.1016\/j.amjms.2020.05.044_bib0053","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1164\/ajrccm\/143.6.1329","article-title":"Effect of inhaled furosemide and bumetanide on adenosine 5\u2032-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects","volume":"143","author":"O'Connor","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.amjms.2020.05.044_bib0054","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1183\/09031936.93.05101184","article-title":"Protective effect of loop diuretics, piretanide and frusemide, against sodium metabisulphite-induced bronchoconstriction in asthma","author":"Yeo","year":"1992","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.104.1.185","article-title":"Protective effect of inhaled piretanide on the bronchial obstructive response to ultrasonically nebulized H2O. A dose-response study","volume":"104","author":"Bianco","year":"1993","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0056","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1038\/s41598-018-27995-w","article-title":"Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B","volume":"8","author":"Hampel","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.amjms.2020.05.044_bib0057","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1378\/chest.07-2294","article-title":"Inhaled mannitol improves lung function in cystic fibrosis","volume":"133","author":"Jaques","year":"2008","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.amjms.2020.05.044_bib0058","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1164\/ajrccm.159.6.9809074","article-title":"Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis","volume":"159","author":"Daviskas","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjms.2020.05.044_bib0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1465-9921-12-11","article-title":"Airway inflammation and mannitol challenge test in COPD","volume":"12","author":"Nijs","year":"2011","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.amjms.2020.05.044_bib0060","doi-asserted-by":"crossref","first-page":"e2011122","DOI":"10.1001\/jamanetworkopen.2020.11122","article-title":"Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China","volume":"3","author":"Chen","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.amjms.2020.05.044_bib0061","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/0004563220922255","article-title":"Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19)","volume":"57","author":"Lippi","year":"2020","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"10.1016\/j.amjms.2020.05.044_bib0062","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0002-8703(77)80337-2","article-title":"Clinical toxicity of furosemide in hospitalized patients","volume":"94","author":"Greenblatt","year":"1977","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjms.2020.05.044_bib0063","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphys.2018.00086","article-title":"Effect of inhaled nebulized furosemide (40 and 120 mg) on breathlessness during exercise in the presence of external thoracic restriction in healthy men","volume":"9","author":"Waskiw-Ford","year":"2018","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.amjms.2020.05.044_bib0064","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0885-3924(02)00479-7","article-title":"Tookman. Re: nebulized furosemide for dyspnea in terminal cancer patients","volume":"24","author":"Stone","year":"2002","journal-title":"J Pain Symptom Manag"},{"issue":"10235","key":"10.1016\/j.amjms.2020.05.044_bib0065","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","article-title":"SARS-CoV-2 and viral sepsis: observations and hypotheses","volume":"395","author":"Li","year":"2020","journal-title":"Lancet"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296292030238X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296292030238X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:37:42Z","timestamp":1757702262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296292030238X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S000296292030238X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2020.05.044","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Inhaled Furosemide a Potential Therapeutic for COVID-19?","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2020.05.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}